AI Engines For more Details: Perplexity Kagi Labs You
Migraine Relief: Parthenolide has been studied for its ability to reduce the frequency and severity of migraines. It is believed to exert its effects by inhibiting the release of certain chemicals in the brain that contribute to migraine symptoms. However, individual responses may vary, and more research is needed to fully understand its effectiveness.
Anti-inflammatory Properties: Parthenolide exhibits anti-inflammatory properties, which may be beneficial for conditions involving inflammation, such as arthritis. It can help reduce pain and swelling associated with inflammatory conditions, although more research is needed to determine its efficacy and safety for long-term use.
Potential Side Effects: While parthenolide is generally well-tolerated, some individuals may experience side effects such as gastrointestinal upset, including nausea and diarrhea. Allergic reactions are also possible in sensitive individuals.
Drug Interactions: Parthenolide may interact with certain medications, including blood-thinning medications (anticoagulants) such as warfarin, and drugs metabolized by the liver. It's important to consult with a healthcare professional before using parthenolide supplements, especially if you are taking other medications.
Pregnancy and Lactation: There is limited information available regarding the safety of parthenolide supplements during pregnancy and lactation. Pregnant and breastfeeding women should exercise caution and consult with a healthcare provider before using these supplements.
Quality and Dosage: The quality and dosage of parthenolide supplements can vary between products. It's essential to choose reputable brands and follow dosing instructions carefully to ensure safety and effectiveness.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Escherichia coli | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.5 | 0.5 | |
| ADHD | 2.1 | 2.1 | |
| Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.4 | 0.25 |
| Allergic Rhinitis (Hay Fever) | 1.8 | 1.6 | 0.13 |
| Allergies | 2.8 | 1 | 1.8 |
| Allergy to milk products | 1.2 | 1.3 | -0.08 |
| Alzheimer's disease | 4 | 3 | 0.33 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.4 | 0.7 | 1 |
| Ankylosing spondylitis | 1.9 | 0.6 | 2.17 |
| Anorexia Nervosa | 0.9 | 1.9 | -1.11 |
| Antiphospholipid syndrome (APS) | 1.2 | 0.3 | 3 |
| Asthma | 2.9 | 1.3 | 1.23 |
| Atherosclerosis | 1.8 | 0.8 | 1.25 |
| Atrial fibrillation | 1.6 | 1.6 | 0 |
| Autism | 4.5 | 4.9 | -0.09 |
| Autoimmune Disease | 0.9 | 0.7 | 0.29 |
| Barrett esophagus cancer | 0.3 | 0.3 | 0 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 2.1 | 2.1 | |
| Bipolar Disorder | 1.8 | 0.5 | 2.6 |
| Brain Trauma | 0.3 | 0.8 | -1.67 |
| Breast Cancer | 1.2 | 1.2 | |
| Cancer (General) | 0.3 | 0.5 | -0.67 |
| Carcinoma | 2.8 | 0.7 | 3 |
| Celiac Disease | 2.5 | 1.1 | 1.27 |
| Cerebral Palsy | 0.8 | 0.8 | 0 |
| Chronic Fatigue Syndrome | 2.2 | 1.8 | 0.22 |
| Chronic Kidney Disease | 1.3 | 0.9 | 0.44 |
| Chronic Lyme | 0.8 | -0.8 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.8 | 1.1 | 0.64 |
| Chronic Urticaria (Hives) | 1.7 | 0.7 | 1.43 |
| Coagulation / Micro clot triggering bacteria | 1.9 | 0.8 | 1.37 |
| Cognitive Function | 1 | 1 | 0 |
| Colorectal Cancer | 6.7 | 1.9 | 2.53 |
| Constipation | 1.5 | 0.5 | 2 |
| Coronary artery disease | 1.5 | 1.5 | 0 |
| COVID-19 | 4.7 | 3.1 | 0.52 |
| Crohn's Disease | 6 | 2.4 | 1.5 |
| Cushing's Syndrome (hypercortisolism) | 0.9 | -0.9 | |
| cystic fibrosis | 1.2 | 0.8 | 0.5 |
| d-lactic acidosis (one form of brain fog) | 0.6 | 0.6 | |
| deep vein thrombosis | 2.5 | 1.1 | 1.27 |
| Denture Wearers Oral Shifts | 0.9 | 0.9 | |
| Depression | 6.6 | 3.3 | 1 |
| Dermatomyositis | 0.3 | 0.3 | |
| Eczema | 1.4 | 1.1 | 0.27 |
| Endometriosis | 2.2 | 1.2 | 0.83 |
| Eosinophilic Esophagitis | 0.3 | 0.3 | 0 |
| Epilepsy | 3.2 | 1 | 2.2 |
| erectile dysfunction | 1.4 | 1.4 | |
| Fibromyalgia | 1.7 | 1 | 0.7 |
| Functional constipation / chronic idiopathic constipation | 3.7 | 2.1 | 0.76 |
| gallstone disease (gsd) | 2.5 | 0.9 | 1.78 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 2.1 | 0.3 | 6 |
| Generalized anxiety disorder | 2.1 | 0.8 | 1.63 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 0.6 | 0.3 | 1 |
| Graves' disease | 0.7 | 1.1 | -0.57 |
| Gulf War Syndrome | 0.5 | 1.1 | -1.2 |
| Halitosis | 1.5 | 0.3 | 4 |
| Hashimoto's thyroiditis | 1.8 | 0.6 | 2 |
| Heart Failure | 3 | 0.6 | 4 |
| hemorrhagic stroke | 0.7 | 0.7 | |
| Hidradenitis Suppurativa | 1.2 | 1.2 | |
| High Histamine/low DAO | 1.8 | 1.8 | |
| hypercholesterolemia (High Cholesterol) | 0.8 | 0.1 | 7 |
| hyperglycemia | 1.8 | 0.9 | 1 |
| Hyperlipidemia (High Blood Fats) | 0.3 | 0.3 | |
| hypersomnia | 0.3 | -0.3 | |
| hypertension (High Blood Pressure | 1.9 | 2.4 | -0.26 |
| Hypothyroidism | 0.1 | 0.1 | |
| Hypoxia | 2.7 | 2.7 | |
| IgA nephropathy (IgAN) | 1.3 | 1.5 | -0.15 |
| Inflammatory Bowel Disease | 5.5 | 3.5 | 0.57 |
| Insomnia | 0.6 | 1.3 | -1.17 |
| Intelligence | 1.6 | 1.6 | |
| Intracranial aneurysms | 1 | 1 | |
| Irritable Bowel Syndrome | 4.2 | 3.1 | 0.35 |
| ischemic stroke | 1.6 | 1.4 | 0.14 |
| Liver Cirrhosis | 4.3 | 3.3 | 0.3 |
| Long COVID | 3.2 | 2.2 | 0.45 |
| Low bone mineral density | 0.5 | -0.5 | |
| Lung Cancer | 0.9 | 0.1 | 8 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 1.5 | 1.5 | |
| ME/CFS with IBS | 0.5 | 0.3 | 0.67 |
| ME/CFS without IBS | 0.5 | 0.3 | 0.67 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.3 | 0.6 | -1 |
| Metabolic Syndrome | 4.7 | 4.3 | 0.09 |
| Mood Disorders | 5.9 | 2.6 | 1.27 |
| multiple chemical sensitivity [MCS] | 0.4 | 0.4 | |
| Multiple Sclerosis | 4 | 2.8 | 0.43 |
| Multiple system atrophy (MSA) | 0.8 | 0.8 | |
| myasthenia gravis | 0.9 | 0.7 | 0.29 |
| neuropathic pain | 1.3 | -1.3 | |
| Neuropathy (all types) | 0.3 | 1.6 | -4.33 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.9 | 0.9 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 3.2 | 1 | 2.2 |
| NonCeliac Gluten Sensitivity | 0.4 | 0.3 | 0.33 |
| Obesity | 4.3 | 4.1 | 0.05 |
| obsessive-compulsive disorder | 4 | 0.7 | 4.71 |
| Osteoarthritis | 2.3 | 0.6 | 2.83 |
| Osteoporosis | 1.6 | 0.7 | 1.29 |
| pancreatic cancer | 0.9 | 0.3 | 2 |
| Parkinson's Disease | 4.7 | 3.6 | 0.31 |
| Polycystic ovary syndrome | 4 | 1.7 | 1.35 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.2 | |
| Premenstrual dysphoric disorder | 0.4 | -0.4 | |
| primary biliary cholangitis | 0.3 | 1.3 | -3.33 |
| Primary sclerosing cholangitis | 2.1 | 0.6 | 2.5 |
| Psoriasis | 1.8 | 1.4 | 0.29 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 3.1 | 1.9 | 0.63 |
| Rosacea | 0.7 | -0.7 | |
| Schizophrenia | 2.9 | 1.5 | 0.93 |
| scoliosis | 0.6 | 0.3 | 1 |
| Sjögren syndrome | 1.3 | 1.3 | 0 |
| Sleep Apnea | 0.3 | 0.8 | -1.67 |
| Slow gastric motility / Gastroparesis | 0.9 | 0.9 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.7 | 1.7 | |
| Stress / posttraumatic stress disorder | 2.4 | 1.4 | 0.71 |
| Systemic Lupus Erythematosus | 3 | 0.9 | 2.33 |
| Tic Disorder | 0.9 | 0.9 | |
| Tourette syndrome | 0.3 | 0.3 | 0 |
| Type 1 Diabetes | 3 | 1.9 | 0.58 |
| Type 2 Diabetes | 4.9 | 4.9 | 0 |
| Ulcerative colitis | 5.1 | 4 | 0.27 |
| Unhealthy Ageing | 3 | 1 | 2 |
| Vitiligo | 1.6 | 0.7 | 1.29 |
